Merck & Co., Inc.

FDA Panel Backs Merck Insomnia Drug Suvorexant, But At Lower Doses

FDA panel favours Merck sleeping aid despite safety concerns over drowsiness, driving issues

FDA panel backs experimental Merck insomnia drug

Merck Statement on FDA Advisory Committee Meeting for Suvorexant

FDA panel votes 13-3 that Merck insomnia drug safe in low doses, Bloomberg says

Options Update; May 22, 2013

Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of Directors

FDA panel says Merck insomnia drug effective as sleep aid, Bloomberg reports

Nigeria Applauds Progress Made by Merck’s Praziquantel Donation Program

Alchemia Limited Company Update